Ponatinib is a type of medicine called a kinase inhibitor. It works by blocking the activity of certain proteins called kinases, specifically the BCR::ABL protein and its mutated forms, including the T315I mutation. These proteins are involved in the growth and survival of cancer cells in certain blood cancers, such as Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).

By blocking these kinases, ponatinib helps stop the cancer cells from growing and may lead to their death. It also inhibits other kinases involved in blood vessel growth and cell signaling, which may further help control the spread of cancer. Ponatinib is especially important for patients whose cancer has not responded to other treatments or who have specific mutations that make other medicines less effective.

ponatinib

Common brand names

Approved use in